← Leaderboards
Sarah H. Elsea
Michigan State University
$3,970,721
Attributed
$4,214,731
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $673.8K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,214,731 · 4
By mechanism
R01$3,726,711 · 2
R21$413,270 · 1
R03$74,750 · 1
Top collaborators
- Stephanie Renee Sisley2 shared
- James A Lister1 shared
Others in their field
Top investigators on “Phenotype”
- David R. Weir · University Of Michigan At Ann Arbor$239,033,262
- David Heimbrook · Leidos Biomedical Research, Inc.$213,586,034
- Constance Ann Benson · University Of California, San Diego$187,132,366
- Richard A Gibbs · Baylor College Of Medicine$184,906,270
- James E. Gern · University Of Wisconsin-Madison$141,704,104
- Garret A Fitzgerald · University Of Pennsylvania$141,348,491
Research focus
PhenotypeResponseMetabolicCellsPathway InteractionsOxidative StressOxidation-ReductionGenesNadpSleep DisordersProductionMutationGeneticMalignant NeoplasmsReactive Oxygen SpeciesGene ExpressionMalignant Neoplasm Of PancreasPancreatic Ductal AdenocarcinomaAllelesGlutaminePancreasMouse ModelMetabolic PathwayAntioxidants
Grant awards (16)
REFINING METRICS OF FOOD BEHAVIOR IN SMITH-MAGENIS SYNDROME$187,850
R21 · FY2023 · HD
REFINING METRICS OF FOOD BEHAVIOR IN SMITH-MAGENIS SYNDROME$225,420
R21 · FY2022 · HD
Preclinical Analyses of NAD Kinase as a Redox Vulnerability for the Treatment of Pancreatic Cancer$452,729
R01 · FY2021 · CA · contact PI
Preclinical Analyses of NAD Kinase as a Redox Vulnerability for the Treatment of Pancreatic Cancer$513,809
R01 · FY2020 · CA · contact PI
Defining cell-intrinsic utilization, cofactor balancing, and metabolomic signatures of NAD+ in pancreatic cancer$160,000
R01 · FY2020 · CA · contact PI
Preclinical Analyses of NAD Kinase as a Redox Vulnerability for the Treatment of Pancreatic Cancer$351,691
R01 · FY2019 · CA · contact PI
NRF2 AND TXN SYSTEM-MEDIATED RESPONSE TO NADK INHIBITION IN PANCREATIC CANCER$61,080
R01 · FY2019 · CA · contact PI
Preclinical Analyses of NAD Kinase as a Redox Vulnerability for the Treatment of Pancreatic Cancer$362,569
R01 · FY2018 · CA · contact PI
NADK and Reactive Oxygen Species in Alzheimer's Disease: Assessing Link to Pancreatic Cancer$291,615
R01 · FY2018 · CA · contact PI
Preclinical Analyses of NAD Kinase as a Redox Vulnerability for the Treatment of Pancreatic Cancer$362,569
R01 · FY2017 · CA · contact PI
Establishing zebrafish as a model for rai1 gene dosage$74,750
R03 · FY2010 · HD · contact PI
Molecular Analysis of del(17)(p11.2)$236,250
R01 · FY2005 · HD
Molecular Analysis of del(17)(p11.2)$236,250
R01 · FY2004 · HD
Molecular Analysis of del(17)(p11.2)$229,586
R01 · FY2003 · HD
Molecular Analysis of del(17)(p11.2)$234,675
R01 · FY2002 · HD
Molecular Analysis of del(17)(p11.2)$233,888
R01 · FY2001 · HD